We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Dose Escalation Study of MK-1775 in Combination With Either Gemcitabine, Cisplatin, or Carboplatin in Adults With Advanced Solid Tumors (MK-1775-001)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00648648
Recruitment Status : Completed
First Posted : April 1, 2008
Results First Posted : April 5, 2019
Last Update Posted : April 5, 2019
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme LLC

Tracking Information
First Submitted Date  ICMJE March 26, 2008
First Posted Date  ICMJE April 1, 2008
Results First Submitted Date  ICMJE May 11, 2018
Results First Posted Date  ICMJE April 5, 2019
Last Update Posted Date April 5, 2019
Actual Study Start Date  ICMJE February 25, 2008
Actual Primary Completion Date January 6, 2014   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: January 9, 2019)
  • Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) [ Time Frame: Part 1: Up to 14 days, Part 2: Up to 28 days ]
    DLTs were adverse events (AEs) considered at least possibly related to study drug that prevented escalation of the drug dose. Hematologic DLTs were any grade (Gr) 4-5 toxicity EXCEPT: Gr 4 anemia and Gr 4 leukopenia, Gr 4 neutropenia lasting for <7 days, Gr 4 thrombocytopenia lasting for <4 days except if a platelet transfusion is required, and Gr 3/Gr 4 neutropenia with fever >38.5°C and/or infection requiring antibiotic or anti-fungal treatment. Non-hematologic DLT was defined as any Gr 3, 4, or 5 non-hematologic toxicity EXCEPT: nausea, vomiting, diarrhea, or dehydration (all Gr 3) occurring in a setting of inadequate compliance with supportive care measures and lasting for <48 hours, alopecia of any grade, inadequately treated hypersensitivity reactions, and clinically non-significant, treatable or reversible lab abnormalities including liver function tests, uric acid, etc.
  • Percentage of Total Cyclin-dependent Kinase (CDC2)-Positive Cells That Were Phosphorylated (pCDC2) in Skin Cells at Baseline and 8 Hours After MK-1775 Dosing [ Time Frame: Baseline, 8 hours after first MK-1775 dose ]
    The pCDC2 level in skin cells was used as a marker to evaluate MK-1775 activity. Analysis was done by immunohistochemistry and the percentage of total CDC2-positive cells that were pCDC2 positive (% pCDC2-positive cells) at baseline and 8 hours after MK-1775 dosing were reported for participants in Part 1, 2-A, and 2-B/3 treatment groups with available data per protocol.
  • Percentage of Total pCDC2 in Skin Cells at Baseline and 24 Hours After MK-1775 Dosing [ Time Frame: Baseline, 24 hours after first MK-1775 dose ]
    The pCDC2 level in skin cells was used as a marker to evaluate MK-1775 activity. Analysis was done by immunohistochemistry and the percentage of total pCDC2 at baseline and 24 hours after MK-1775 dosing were reported for participants in the Part 2-B/3 MK-1775 QD x2 Multi Dose plus Gemcitabine treatment groups with available data per protocol.
  • Percentage of Total pCDC2 in Skin Cells at Baseline and 48 Hours After MK-1775 Dosing [ Time Frame: Baseline, 48 hours after first MK-1775 dose ]
    The pCDC2 level in skin cells was used as a marker to evaluate MK-1775 activity. Analysis was done by immunohistochemistry and the percentage of total pCDC2 at baseline and at 48 hours after MK-1775 dosing were reported for participants in the Part 2-B/3 MK-1775 (150 mg, 200 mg, 250) BID x 2.5 Multi Dose plus cisplatin 75 mg/m^2 groups and the 325 mg BID x2.5 Multi Dose + Carboplatin group with available data per protocol.
  • Plasma Concentration of MK-1775 at 8 Hours After Administration (C8hr) of Single or Multiple Oral Doses [ Time Frame: 8 hours after MK-1775 dose ]
    MK-1775 was measured in the plasma at 8 hours after dosing (Day 1 for single dose of monotherapy, Day 2 of single-dose combination therapy and QD x 2 Combination dosing, and Day 3 dose for BID X 2.5 combination dosing) for participants with available data.
  • Mean Urine Excretion of MK-1775 24 Hours After the Day 1 Monotherapy Dose [ Time Frame: At 0-4 hours, 4-8 hours, and 12-24 hours post Day 1 dose of monotherapy ]
    The mean cumulative amount of MK-1775 excreted unchanged in urine after a single oral dose was measured during the initial monotherapy cycle of the study. For this outcome measure, samples were collected and analyzed only for the MK-1775 monotherapy arms of the study at defined intervals after the Day 1 dose of monotherapy. Part 2 MK-1775 combination arms were not sampled per protocol.
Original Primary Outcome Measures  ICMJE
 (submitted: March 28, 2008)
Dose limiting toxicities; maximum tolerated dose; predictive biomarkers; plasma and urine concentrations of MK1775 and metabolites [ Time Frame: Study will continue until dose limiting toxicity and/or maximum tolerated dose is reached. ]
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: January 9, 2019)
Best Overall Response as Per Response Evaluation Criteria in Solid Tumors (RECIST) Criteria [ Time Frame: From Day 1 up through discontinuation of study treatment (up to ~11.2 months) ]
Best overall response achieved by a participant. Starting at Day 1, participants in Part 2 were evaluated for tumor response every 6-8 weeks until discontinuation from study treatment according to RECIST criteria; which are based on radiographic imaging. Recorded responses were either confirmed by Central Review or unconfirmed (Investigator assessment only), and included complete response (CR; defined as disappearance of all target lesions), partial response (PR; at least a 30% decrease in the sum of the longest diameter [LD] of target lesions, taking as reference the baseline sum LD), stable disease (SD; neither sufficient shrinkage to qualify for PR nor sufficient growth to qualify for PD, taking as reference the smallest sum LD since the treatment started), or progressive disease (PD; ≥20% increase in sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started, or the appearance of one or more new lesions).
Original Secondary Outcome Measures  ICMJE
 (submitted: March 28, 2008)
Disease progression; biologically effective dose [ Time Frame: Tumor progression will be measured on first day of every treatment cycle ]
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE A Dose Escalation Study of MK-1775 in Combination With Either Gemcitabine, Cisplatin, or Carboplatin in Adults With Advanced Solid Tumors (MK-1775-001)
Official Title  ICMJE A Phase I Dose Escalation Study Evaluating MK-1775 in Both Monotherapy and in Combination With Either Gemcitabine, Cisplatin, or Carboplatin in Adult Subjects With Advanced Solid Tumors
Brief Summary This study will investigate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) activity of MK-1775, both as monotherapy and in combination with gemcitabine, cisplatin, or carboplatin in participants with advanced solid tumors. Dose limiting toxicities (DLT) of MK-1775 in combination with gemcitabine, cisplatin, or carboplatin will also be assessed. The primary hypotheses of the study are as follows: 1) Oral administration of MK-1775 both as monotherapy and in combination with either gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors will be safe and tolerable, 2) The side effects observed in participants with advanced solid tumors after administration of MK-1775 combined with each of the chemotherapies (gemcitabine, cisplatin and carboplatin) will allow for the definition of a single dose combination Maximum Administered Dose (MAD)/Maximum Tolerated Dose (MTD) and a multiple dose combination Biologically Effective Dose (BED)/MTD for each of the 3 combinations, 3) At a tolerated dose, MK-1775 plasma exposure will exceed target thresholds established in preclinical models, and 4) At a tolerated dose, PD markers of MK-1775 activity in combination with either gemcitabine, cisplatin, or carboplatin (in surrogate tissue and/or tumor) will meet or exceed the target threshold established in preclinical models.
Detailed Description Part 1 consists of single dose MK-1775 monotherapy. If well tolerated, participants in Part 1 will continue on to one of three treatment arms in Part 2-A which consists of a single lower dose of MK-1775 in combination with standard chemotherapy: 1) MK-1775 +Gemcitabine (1000 mg/m^2), 2) MK-1775 + Cisplatin (75 mg/m^2) or 3) MK-1775 +Carboplatin at an area under the time curve concentration of 5 mg/min/ml (AUC5). Following completion of Part 2-A, MK-1775 will be administered twice daily (BID) for 2.5 days (multi-dose) starting concomitantly with each administration of chemotherapy in Part 2-B. After a preliminary combination MTD of MK-1775 and chemotherapy has been established in Part 2B, the MTD confirmation expansion will occur in Part 3.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Solid Tumors
Intervention  ICMJE
  • Drug: MK-1775
    MK-1775 administered as an oral formulation as either monotherapy or in combination with either gemcitabine, cisplatin, or carboplatin.
  • Drug: gemcitabine
    Gemcitabine administered at 1000 mg/m^2 by IV infusion in a 28-day cycle.
  • Drug: cisplatin
    Cisplatin administered at 75 mg/m^2 by IV infusion in a 21-day cycle.
  • Drug: carboplatin
    Carboplatin administered at AUC/time curve of 5 mg/min/mL (AUC5) by IV infusion in a 21-day cycle.
Study Arms  ICMJE
  • Experimental: MK-1775 325 mg Single Dose
    Participants received MK-1775 325 mg, orally, on Day 1.
    Intervention: Drug: MK-1775
  • Experimental: MK-1775 650 mg Single Dose
    Participants received MK-1775 650 mg, orally, on Day 1.
    Intervention: Drug: MK-1775
  • Experimental: MK-1775 1300 mg Single Dose
    Participants received MK-1775 1300 mg, orally, on Day 1.
    Intervention: Drug: MK-1775
  • Experimental: MK-1775 100 mg Single Dose + Gemcitabine 1000 mg/m^2
    Participants received gemcitabine 1000 mg/m^2 as an intravenous (IV) infusion on Days 1, 8, and 15 in each 4-week cycle plus MK-1775 100 mg single dose, orally, on Day 2 of each cycle.
    Interventions:
    • Drug: MK-1775
    • Drug: gemcitabine
  • Experimental: MK-1775 200 mg Single Dose + Gemcitabine 1000 mg/m^2
    Participants received gemcitabine 1000 mg/m^2 as an IV infusion on Days 1, 8, and 15 in each 4-week cycle plus MK-1775 200 mg single dose, orally, on Day 2 of each cycle.
    Interventions:
    • Drug: MK-1775
    • Drug: gemcitabine
  • Experimental: MK-1775 100 mg Single Dose + Cisplatin 75 mg/ m^2
    Participants received cisplatin 75 mg/ m^2 as an IV infusion on Day 1 of each 3 week cycle plus MK-1775 100 mg single dose orally, on Day 2 of each cycle.
    Interventions:
    • Drug: MK-1775
    • Drug: cisplatin
  • Experimental: MK-1775 200 mg Single Dose + Cisplatin 75 mg/ m^2
    Participants received cisplatin 75 mg/ m^2 as an IV infusion on Day 1 of each 3 week cycle plus MK-1775 200 mg single dose orally, on Day 2 of each cycle.
    Interventions:
    • Drug: MK-1775
    • Drug: cisplatin
  • Experimental: MK-1775 100 mg Single Dose + Carboplatin AUC 5
    Participants received carboplatin at an area under the time curve concentration of 5 mg/min/ml (AUC5) as an IV infusion on Day 1 of each 3 week cycle plus MK-1775 100 mg single dose orally, on Day 2 of each cycle.
    Interventions:
    • Drug: MK-1775
    • Drug: carboplatin
  • Experimental: MK-1775 200 mg Single Dose + Carboplatin AUC 5
    Participants received carboplatin AUC5 as an IV infusion on Day 1 of each 3 week cycle plus MK-1775 200 mg single dose orally, on Day 2 of each cycle.
    Interventions:
    • Drug: MK-1775
    • Drug: carboplatin
  • Experimental: MK-1775 325 mg Single Dose + Carboplatin AUC 5
    Participants received carboplatin AUC5 as an IV infusion on Day 1 of each 3 week cycle plus MK-1775 325 mg single dose orally, on Day 2 of each cycle.
    Interventions:
    • Drug: MK-1775
    • Drug: carboplatin
  • Experimental: MK-1775 25 mg BID x2.5 Multi Dose + Gemcitabine 1000 mg/ m^2
    Participants received gemcitabine 1000 mg/m^2 as an IV infusion on Days 1, 8, and 15 of each 4-week cycle plus MK-1775 25 mg orally twice daily (BID) for 2.5 days, starting concomitantly with the IV infusion of gemcitabine on Day 1 and followed by 4 additional doses of MK-1775 25 mg at approximately 12 hour intervals on Days 1-3, 8-9, and 15-17 of each cycle.
    Interventions:
    • Drug: MK-1775
    • Drug: gemcitabine
  • Experimental: MK-1775 50/25 mg BID x2.5 Multi + Gemcitabine 1000 mg/ m^2
    Participants received gemcitabine 1000 mg/m^2 as an IV infusion on Days 1, 8, and 15 of each 4 week cycle plus MK-1775 50 mg orally BID for 2.5 days, starting concomitantly with the IV infusion of gemcitabine on Day 1 and followed by 4 doses of MK-1775 25 mg at approximately 12 hour intervals on Days 1-3, 8-9, and 15-17 of each 4 week cycle.
    Interventions:
    • Drug: MK-1775
    • Drug: gemcitabine
  • Experimental: MK-1775 50 mg BID x2.5 Multi + Gemcitabine 1000 mg/ m^2
    Participants received gemcitabine 1000 mg/m^2 as an IV infusion given once weekly for 3 consecutive weeks of a 4 week cycle plus MK-1775 50 mg orally BID for 2.5 days, starting concomitantly with the IV infusion of gemcitabine on Day 1 and followed by 4 additional doses of MK-1775 50 mg at approximately 12 hour intervals on Days 1-3, 8-9, and 15-17 of each 4 week cycle.
    Interventions:
    • Drug: MK-1775
    • Drug: gemcitabine
  • Experimental: MK-1775 100 mg QD x2 Multi + Gemcitabine 1000 mg/ m^2
    Participants received gemcitabine 1000 mg/m^2 as an IV infusion on Days 1, 8, and 15 of each 4 week cycle plus MK-1775 100 mg orally once daily (QD) on Days 1, 2, 8, 9, 15, and 16 of each 4 week cycle.
    Interventions:
    • Drug: MK-1775
    • Drug: gemcitabine
  • Experimental: MK-1775 125 mg QD x2 Multi + Gemcitabine 1000 mg/ m^2
    Participants received gemcitabine 1000 mg/m^2 as an IV infusion on Days 1, 8, and 15 of each 4 week cycle plus MK-1775 125 mg orally QD on Days 1, 2, 8, 9, 15, and 16 of each 4 week cycle.
    Interventions:
    • Drug: MK-1775
    • Drug: gemcitabine
  • Experimental: MK-1775 150 mg QD x2 Multi + Gemcitabine 1000 mg/ m^2
    Participants received gemcitabine 1000 mg/m^2 as an IV infusion on Days 1, 8, and 15 of each 4 week cycle plus MK-1775 150 mg orally QD on Days 1, 2, 8, 9, 15, and 16 of each 4 week cycle.
    Interventions:
    • Drug: MK-1775
    • Drug: gemcitabine
  • Experimental: MK-1775 175 mg QD x2 Multi Dose + Gemcitabine 1000 mg/ m^2
    Participants received gemcitabine 1000 mg/m^2 as an IV infusion given on Days 1, 8, and 15 of each 4 week cycle plus MK-1775 175 mg orally QD on Days 1, 2, 8, 9, 15, and 16 of each 4 week cycle.
    Interventions:
    • Drug: MK-1775
    • Drug: gemcitabine
  • Experimental: MK-1775 200 mg QD x2 Multi Dose + Gemcitabine 1000 mg/ m^2
    Participants received gemcitabine 1000 mg/m^2 as an IV infusion on Days 1, 8, and 15 of each 4 week cycle plus MK-1775 200 mg orally QD on Days 1, 2, 8, 9, 15, and 16 of each 4 week cycle.
    Interventions:
    • Drug: MK-1775
    • Drug: gemcitabine
  • Experimental: MK-1775 50 mg BID x2.5 Multi Dose + Cisplatin 75 mg/ m^2
    Participants received cisplatin 75 mg/ m^2 as an IV infusion on Day 1 of each 3 week cycle plus MK-1775 50 mg orally BID for 2.5 days, starting concomitantly with the administration of cisplatin on Day 1 and then at 12 hour intervals on Days 1-3 of each 3 week cycle.
    Interventions:
    • Drug: MK-1775
    • Drug: cisplatin
  • Experimental: MK-1775 100 mg BID x2.5 Multi Dose + Cisplatin 75 mg/ m^2
    Participants received cisplatin 75 mg/ m^2 as an IV infusion on Day 1 of each 3 week cycle plus MK-1775 100 mg orally BID for 2.5 days, starting concomitantly with the administration of cisplatin on Day 1 and then at 12 hour intervals on Days 1-3 of each 3 week cycle.
    Interventions:
    • Drug: MK-1775
    • Drug: cisplatin
  • Experimental: MK-1775 125 mg BID x2.5 Multi Dose + Cisplatin 75 mg/ m^2
    Participants received cisplatin 75 mg/ m^2 as an IV infusion on Day 1 of each 3 week cycle plus MK-1775 125 mg orally BID for 2.5 days, starting concomitantly with the administration of cisplatin on Day 1 and then at 12 hour intervals on Days 1-3 of each 3 week cycle.
    Interventions:
    • Drug: MK-1775
    • Drug: cisplatin
  • Experimental: MK-1775 150 mg BID x2.5 Multi Dose + Cisplatin 75 mg/ m^2
    Participants received cisplatin 75 mg/ m^2 as an IV infusion on Day 1 of each 3 week cycle plus MK-1775 150 mg orally BID for 2.5 days, starting concomitantly with the administration of cisplatin on Day 1 and then at 12 hour intervals on Days 1-3 of each 3 week cycle.
    Interventions:
    • Drug: MK-1775
    • Drug: cisplatin
  • Experimental: MK-1775 200 mg BID x2.5 Multi Dose + Cisplatin 75 mg/ m^2
    Participants received cisplatin 75 mg/ m^2 as an IV infusion on Day 1 of each 3 week cycle plus MK-1775 200 mg orally BID for 2.5 days, starting concomitantly with the administration of cisplatin on Day 1 and then at 12 hour intervals on Days 1-3 of each 3 week cycle.
    Interventions:
    • Drug: MK-1775
    • Drug: cisplatin
  • Experimental: MK-1775 250 mg BID x2.5 Multi Dose + Cisplatin 75 mg/ m^2
    Participants received cisplatin 75 mg/ m^2 as an IV infusion on Day 1 of each 3 week cycle plus MK-1775 250 mg orally BID for 2.5 days, starting concomitantly with the administration of cisplatin on Day 1 and then at 12 hour intervals on Days 1-3 of each 3 week cycle.
    Interventions:
    • Drug: MK-1775
    • Drug: cisplatin
  • Experimental: MK-1775 75 mg BID x2.5 Multi Dose + Carboplatin AUC 5
    Participants received carboplatin AUC 5 as an IV infusion on Day 1 of each 3 week cycle plus MK-1775 75 mg orally BID for 2.5 days, starting concomitantly with the administration of carboplatin on Day 1 and then at 12 hour intervals on Days 1-3 of each 3 week cycle.
    Interventions:
    • Drug: MK-1775
    • Drug: carboplatin
  • Experimental: MK-1775 150 mg BID x 2.5 Multi Dose + Carboplatin AUC 5
    Participants received carboplatin AUC 5 as an IV infusion on Day 1 of each 3 week cycle plus MK-1775 150 mg orally BID for 2.5 days, starting concomitantly with the administration of carboplatin on Day 1 and then at 12 hour intervals on Days 1-3 of each 3 week cycle.
    Interventions:
    • Drug: MK-1775
    • Drug: carboplatin
  • Experimental: MK-1775 225 mg BID x2.5 Multi Dose + Carboplatin AUC 5
    Participants received carboplatin AUC 5 as an IV infusion on Day 1 of each 3 week cycle plus MK-1775 225 mg orally BID for 2.5 days, starting concomitantly with the administration of carboplatin on Day 1 and then at 12 hour intervals on Days 1-3 of each 3 week cycle.
    Interventions:
    • Drug: MK-1775
    • Drug: carboplatin
  • Experimental: MK-1775 325 mg BID x2.5 Multi Dose + Carboplatin AUC 5
    Participants received carboplatin AUC 5 as an IV infusion on Day 1 of each 3 week cycle plus MK-1775 325 mg orally BID for 2.5 days, starting concomitantly with the administration of carboplatin on Day 1 and then at 12 hour intervals on Days 1-3 of each 3 week cycle.
    Interventions:
    • Drug: MK-1775
    • Drug: carboplatin
Publications * Leijen S, van Geel RM, Pavlick AC, Tibes R, Rosen L, Razak AR, Lam R, Demuth T, Rose S, Lee MA, Freshwater T, Shumway S, Liang LW, Oza AM, Schellens JH, Shapiro GI. Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors. J Clin Oncol. 2016 Dec 20;34(36):4371-4380. doi: 10.1200/JCO.2016.67.5991. Epub 2016 Oct 31.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: January 9, 2019)
206
Original Estimated Enrollment  ICMJE
 (submitted: March 28, 2008)
155
Actual Study Completion Date  ICMJE January 6, 2014
Actual Primary Completion Date January 6, 2014   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Must have a histologically confirmed metastatic or locally advanced solid tumor, progressed despite standard therapy, or for which standard therapy does not exist
  • Must have performance status of <=1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale
  • Female participants must not be pregnant

Exclusion Criteria:

  • Has had chemotherapy, radiotherapy, or biological therapy within 4 weeks prior to entering the study or who has not recovered from adverse events due to agents given more than 4 weeks earlier
  • Is participating or has participated in a study with an investigational compound or device within 30 days
  • Has active central nervous system (CNS) metastases and/or carcinomatous meningitis. However, participants with CNS metastases who have completed a course of therapy would be eligible for the study provided they are clinically stable for 1 month prior to entry
  • Has a primary central nervous system tumor
  • Is allergic to any of the components of the combination study therapy or its analogs
  • Participant has had prescription or non-prescription drugs or other products known to be metabolized by Cytochrome P450 3A4 (CYP3A4) that cannot be discontinued prior to Day 1 of dosing and withheld throughout the study until 2 weeks after the last dose of study medication. Medications of particular concern are inhibitors of CYP3A4 (azole antifungals [ketoconazole, itraconazole], macrolide antibiotics [erythromycin, clarithromycin], cimetidine, aprepitant, Human Immunodeficiency Virus (HIV) protease inhibitors, nefrazodone, and the following inducers of CYP3A4: phenytoin, barbiturates and rifampicin, and substrates of CYP3A4 including statins (lovastatin, simvastatin), midazolam, terfenadine, astemizole, and cisapride
  • Is a regular user (including "recreational use") of any illicit drugs or had a recent history (within the last year) of drug or alcohol abuse
  • Pregnant or breastfeeding, or expecting to get pregnant during the time the study will be ongoing
  • HIV-positive
  • History of Hepatitis B or C
  • Has symptomatic ascites or pleural effusion. A participant who is clinically stable following treatment for these conditions is eligible
  • Participant must not have prior radiation therapy to more than 30% of the bone marrow and must have recovered for at least 3 weeks from the hematologic toxicity of prior radiotherapy
  • Has had a prior stem cell or bone marrow transplant
  • Has received more than 4 prior cytotoxic chemotherapy regimens
  • Has a history suggestive of Li-Fraumeni Syndrome
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Not Provided
Removed Location Countries Canada,   Netherlands,   United States
 
Administrative Information
NCT Number  ICMJE NCT00648648
Other Study ID Numbers  ICMJE 1775-001
2007_611 ( Other Identifier: Merck Registration Number )
2007-005304-40 ( EudraCT Number )
MK-1775-001 ( Other Identifier: Merck Protocol Number )
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE
Plan to Share IPD: Yes
Plan Description: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
URL: http://engagezone.msd.com/ds_documentation.php
Current Responsible Party Merck Sharp & Dohme LLC
Original Responsible Party Executive Vice President, Clinical and Quantitative Sciences, Merck & Co., Inc.
Current Study Sponsor  ICMJE Merck Sharp & Dohme LLC
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Medical Director Merck Sharp & Dohme LLC
PRS Account Merck Sharp & Dohme LLC
Verification Date January 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP